The purpose of this study is to monitor the use in routine clinical practice of REKOVELLE®. This study will collect information from patients who never underwent previous in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatments for up to three consecutive treatment cycles. The ovarian stimulation protocol with REKOVELLE®, a new recombinant human Follicle Stimulating Hormone (FSH) prescribed for ovarian stimulation, is individualised with a dosing regimen that is based on two parameters: the body weight and the level of a hormone, the Anti Müllerian Hormone, (AMH), a parameter used to predict how the ovaries will respond to the ovarian stimulation.
Age range
18 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Use of algorithm-based individualised dosing regimen to decide daily dose of REKOVELLE®
Timeframe: At consultation visit where the daily dose of REKOVELLE® is decided
Use of the dosing App
Timeframe: At consultation visit where the daily dose of REKOVELLE® is decided
Daily dose of REKOVELLE® in micrograms
Timeframe: From day 1 up to day 20 of REKOVELLE® stimulation
Number of days of treatment with REKOVELLE®
Timeframe: From day 1 up to day 20 of REKOVELLE® stimulation
Day of REKOVELLE® stimulation start
Timeframe: At the day of the first REKOVELLE® injection during the ovarian stimulation treatment
Day of REKOVELLE® stimulation end
Timeframe: At the day of the last REKOVELLE® injection during the ovarian stimulation treatment
Type of GnRH used for Lutenizing Hormone(LH) surge suppression
Timeframe: At consultation visit where the LH surge suppression protocol is decided
Day of LH surge suppression protocol start
Timeframe: At the day of the first GnRH administration during the ovarian stimulation treatment
Day of LH surge suppression protocol end
Timeframe: At the day of the last GnRH administration during the ovarian stimulation treatment
Type of drug used for the triggering of follicle maturation
Timeframe: At consultation visit where the triggering of follicle maturation protocol is decided
Date of administration of hCG and/or GnRH for follicle maturation
Timeframe: At the day of administration (at the discretion of the investigator)
Type of drug used for Luteal phase support
Timeframe: From ovum pick-up day (the length of luteal phase support is decided at the discretion of the investigator)
Parameters used to define the daily dose of REKOVELLE® in case a new assisted reproductive technology treatment is initiated
Timeframe: At consultation visit where the ovarian stimulation treatment strategy is decided